The rationale of a peptide-conjugate vaccine against measles

Mike M. Pütz; Claude P. Muller

doi:10.1016/S0264-410X(02)00576-5

The rationale of a peptide-conjugate vaccine against measles

Mike M. Pütz, Claude P. Muller^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

15 Citations (Scopus)

Abstract

The live-attenuated measles vaccine is poorly immunogenic in infants because of immune suppressive maternal antibodies and immaturity of the infant's immune system. Selected peptides corresponding to sequential, subdominant B cell epitopes of measles virus (MV) glycoproteins have been shown to induce neutralizing and protective antibodies even in the presence of whole virus antibodies. Similar to polysaccharide-conjugate vaccines, which are highly effective in infants a peptide-conjugate vaccine against measles is proposed. Such a vaccine induces carrier-specific T cells, avoiding measles-specific Th2 cells associated with the risk of atypical measles. This article discusses the rationale of such a strategy and its future potential.

Original language	English
Pages (from-to)	663-666
Number of pages	4
Journal	Vaccine
Volume	21
Issue number	7-8
DOIs	https://doi.org/10.1016/S0264-410X(02)00576-5
Publication status	Published - 30 Jan 2003
Externally published	Yes

Keywords

Atypical measles
Conjugate vaccine
Infant immunization
Measles virus (MV)
Synthetic peptides

Access to Document

10.1016/S0264-410X(02)00576-5

Cite this

@article{1564881efff94e20b4c8370ca318ef3a,

title = "The rationale of a peptide-conjugate vaccine against measles",

abstract = "The live-attenuated measles vaccine is poorly immunogenic in infants because of immune suppressive maternal antibodies and immaturity of the infant's immune system. Selected peptides corresponding to sequential, subdominant B cell epitopes of measles virus (MV) glycoproteins have been shown to induce neutralizing and protective antibodies even in the presence of whole virus antibodies. Similar to polysaccharide-conjugate vaccines, which are highly effective in infants a peptide-conjugate vaccine against measles is proposed. Such a vaccine induces carrier-specific T cells, avoiding measles-specific Th2 cells associated with the risk of atypical measles. This article discusses the rationale of such a strategy and its future potential.",

keywords = "Atypical measles, Conjugate vaccine, Infant immunization, Measles virus (MV), Synthetic peptides",

author = "P{\"u}tz, {Mike M.} and Muller, {Claude P.}",

note = "Funding Information: The authors acknowledge the support provided from the Centre de Recherche Public-Sant{\'e}, the European Union project BIO4-CT98-0242 and the Minist{\`e}re de la Culture, de l{\textquoteright}Enseignement Sup{\'e}rieur et de la Recherche (Bourse BFR to M.M.P.). This work was done by M.M.P. in partial fulfillment of his Ph.D. thesis.",

year = "2003",

month = jan,

day = "30",

doi = "10.1016/S0264-410X(02)00576-5",

language = "English",

volume = "21",

pages = "663--666",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "7-8",

}

TY - JOUR

T1 - The rationale of a peptide-conjugate vaccine against measles

AU - Pütz, Mike M.

AU - Muller, Claude P.

N1 - Funding Information: The authors acknowledge the support provided from the Centre de Recherche Public-Santé, the European Union project BIO4-CT98-0242 and the Ministère de la Culture, de l’Enseignement Supérieur et de la Recherche (Bourse BFR to M.M.P.). This work was done by M.M.P. in partial fulfillment of his Ph.D. thesis.

PY - 2003/1/30

Y1 - 2003/1/30

N2 - The live-attenuated measles vaccine is poorly immunogenic in infants because of immune suppressive maternal antibodies and immaturity of the infant's immune system. Selected peptides corresponding to sequential, subdominant B cell epitopes of measles virus (MV) glycoproteins have been shown to induce neutralizing and protective antibodies even in the presence of whole virus antibodies. Similar to polysaccharide-conjugate vaccines, which are highly effective in infants a peptide-conjugate vaccine against measles is proposed. Such a vaccine induces carrier-specific T cells, avoiding measles-specific Th2 cells associated with the risk of atypical measles. This article discusses the rationale of such a strategy and its future potential.

AB - The live-attenuated measles vaccine is poorly immunogenic in infants because of immune suppressive maternal antibodies and immaturity of the infant's immune system. Selected peptides corresponding to sequential, subdominant B cell epitopes of measles virus (MV) glycoproteins have been shown to induce neutralizing and protective antibodies even in the presence of whole virus antibodies. Similar to polysaccharide-conjugate vaccines, which are highly effective in infants a peptide-conjugate vaccine against measles is proposed. Such a vaccine induces carrier-specific T cells, avoiding measles-specific Th2 cells associated with the risk of atypical measles. This article discusses the rationale of such a strategy and its future potential.

KW - Atypical measles

KW - Conjugate vaccine

KW - Infant immunization

KW - Measles virus (MV)

KW - Synthetic peptides

UR - http://www.scopus.com/inward/record.url?scp=0037472480&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(02)00576-5

DO - 10.1016/S0264-410X(02)00576-5

M3 - Article

C2 - 12531336

AN - SCOPUS:0037472480

SN - 0264-410X

VL - 21

SP - 663

EP - 666

JO - Vaccine

JF - Vaccine

IS - 7-8

ER -

The rationale of a peptide-conjugate vaccine against measles

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this